Literature DB >> 6572555

Inhibition of human malignant melanoma colony-forming cells in vitro by prostaglandin A1.

M D Bregman, F L Meyskens.   

Abstract

The direct effect of continuous exposure to prostaglandins on the cloning efficiency and proliferative capacity of human malignant melanoma colony-forming cells in soft agar was evaluated. Prostaglandin A1 (PGA1) and prostaglandin E1 (PGE1) effected a dose-dependent inhibition of colony formation and proliferative capacity. PGA1 at a concentration of 5 microgram/ml reduced colony formation of cells from human melanoma cell strains C8054, C8130, and C822 by at least 85%. PGA1 also inhibited colony formation of cells obtained directly from biopsies of melanoma tissues from eight patients by greater than 70% at a concentration of 5 microgram/ml. A steep dose-response curve was evident by the little effect of PGA1 on colony formation at a concentration of 0.5 microgram/ml. The mean 50% inhibitory doses for PGA1 and PGE1 were 1.25 and 4.25 microgram/ml, respectively. Prostaglandin A2 was much less effective than PGA1 in inhibiting melanoma colony formation. The related prostaglandins (prostaglandin B1, prostaglandin F1 alpha, and prostaglandin E2 alpha) had little or no effect on colony formation. Overall, these results suggested that the presence of a carbonyl group at position 9 of the cyclopentane ring may be required for inhibitory activity as prostaglandins of the A and E series inhibited human melanoma cell growth. PGA1 and PGE1 did not effect a rise in cyclic adenosine 3':5'-monophosphate levels in C8054 and C8130 cells. However, while alpha-melanocyte-stimulating hormone and prostaglandin F2 alpha did generate a rise in adenosine 3':5'-monophosphate levels in C8054 cells, these hormones had no effect on colony formation. These results are consistent with the notion that the PGA1 and PGE1 inhibition of melanoma colony-forming cells occurs via a noncyclic nucleotide mechanism.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6572555

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Induction of HSP70 gene expression by the antiproliferative prostaglandin PGA2: a growth-dependent response mediated by activation of heat shock transcription factor.

Authors:  N J Holbrook; S G Carlson; A M Choi; J Fargnoli
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

2.  Effects of dimethyl prostaglandin A1 on herpes simplex virus and human immunodeficiency virus replication.

Authors:  M Hughes-Fulford; M S McGrath; D Hanks; S Erickson; L Pulliam
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

3.  Cytotoxicity of combinations of prostaglandin D2 (PGD2) and antitumor drugs for B16 melanoma cells in culture.

Authors:  B K Bhuyan; G J Badiner; E G Adams; R Chase
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

4.  EphA2 as a promoter of melanoma tumorigenicity.

Authors:  Naira V Margaryan; Luigi Strizzi; Daniel E Abbott; Elisabeth A Seftor; M Sambasiva Rao; Mary J C Hendrix; Angela R Hess
Journal:  Cancer Biol Ther       Date:  2009-02-21       Impact factor: 4.742

5.  Growth inhibition of Friend erythroleukaemia cell tumours in vivo by a synthetic analogue of prostaglandin A: an action independent of natural killer-activity.

Authors:  S Marini; A T Palamara; E Garaci; M G Santoro
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

6.  Prostaglandin F2 alpha in benign and malignant breast tumours.

Authors:  I B Vergote; G M Laekeman; G H Keersmaekers; F L Uyttenbroeck; J S Vanderheyden; G P Albertyn; C F Haensch; G J De Roy; A G Herman
Journal:  Br J Cancer       Date:  1985-06       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.